478 related articles for article (PubMed ID: 34203237)
21. Unveiling the mechanism of action of nature-inspired anti-cancer compounds using a multi-omics approach.
Soares NC; Ali A; Srinivasulu V; Sharaf BM; Giddey AD; Okendo J; Al-Hroub HM; Semreen MH; Hamad M; Al-Tel TH
J Proteomics; 2022 Aug; 265():104660. PubMed ID: 35728772
[TBL] [Abstract][Full Text] [Related]
22. Omics Biomarkers in Obesity: Novel Etiological Insights and Targets for Precision Prevention.
Aleksandrova K; Egea Rodrigues C; Floegel A; Ahrens W
Curr Obes Rep; 2020 Sep; 9(3):219-230. PubMed ID: 32594318
[TBL] [Abstract][Full Text] [Related]
23. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality.
Guillot N; Roméo B; Manesh SS; Milano G; Brest P; Zitvogel L; Hofman P; Mograbi B
Trends Mol Med; 2023 Nov; 29(11):897-911. PubMed ID: 37704493
[TBL] [Abstract][Full Text] [Related]
24. How Omics Data Can Be Used in Nephrology.
Rhee EP
Am J Kidney Dis; 2018 Jul; 72(1):129-135. PubMed ID: 29478865
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant immunotherapy in colorectal cancer beyond immune checkpoint inhibitors: emerging from bench to bedside.
Kanani A; Veen T; Alexeeva M; Lea D; Søreide K
Minerva Surg; 2023 Aug; 78(4):385-400. PubMed ID: 36940110
[TBL] [Abstract][Full Text] [Related]
26. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
Yuan J; Khilnani A; Brody J; Andtbacka RHI; Hu-Lieskovan S; Luke JJ; Diab A; Marabelle A; Snyder A; Cao ZA; Hodi FS
Eur J Cancer; 2021 Nov; 157():493-510. PubMed ID: 34561127
[TBL] [Abstract][Full Text] [Related]
27. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Nuñez NG; Berner F; Friebel E; Unger S; Wyss N; Gomez JM; Purde MT; Niederer R; Porsch M; Lichtensteiger C; Kramer R; Erdmann M; Schmitt C; Heinzerling L; Abdou MT; Karbach J; Schadendorf D; Zimmer L; Ugurel S; Klümper N; Hölzel M; Power L; Kreutmair S; Capone M; Madonna G; Cevhertas L; Heider A; Amaral T; Hasan Ali O; Bomze D; Dimitriou F; Diem S; Ascierto PA; Dummer R; Jäger E; Driessen C; Levesque MP; van de Veen W; Joerger M; Früh M; Becher B; Flatz L
Med; 2023 Feb; 4(2):113-129.e7. PubMed ID: 36693381
[TBL] [Abstract][Full Text] [Related]
28. Application of omics- and multi-omics-based techniques for natural product target discovery.
Zhang HW; Lv C; Zhang LJ; Guo X; Shen YW; Nagle DG; Zhou YD; Liu SH; Zhang WD; Luan X
Biomed Pharmacother; 2021 Sep; 141():111833. PubMed ID: 34175822
[TBL] [Abstract][Full Text] [Related]
29. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
30. Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review.
Bourbonne V; Geier M; Schick U; Lucia F
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740259
[TBL] [Abstract][Full Text] [Related]
31. Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response.
Valenti F; Falcone I; Ungania S; Desiderio F; Giacomini P; Bazzichetto C; Conciatori F; Gallo E; Cognetti F; Ciliberto G; Morrone A; Guerrisi A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917181
[TBL] [Abstract][Full Text] [Related]
32. Single-cell sequencing: expansion, integration and translation.
Dai X; Cai L; He F
Brief Funct Genomics; 2022 Jul; 21(4):280-295. PubMed ID: 35753690
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction.
Cao T; Zhou X; Wu X; Zou Y
Front Immunol; 2023; 14():1207544. PubMed ID: 37497220
[TBL] [Abstract][Full Text] [Related]
34. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
35. Integrative Analysis of Multi-omics Data for Discovery and Functional Studies of Complex Human Diseases.
Sun YV; Hu YJ
Adv Genet; 2016; 93():147-90. PubMed ID: 26915271
[TBL] [Abstract][Full Text] [Related]
36. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
Front Immunol; 2021; 12():757047. PubMed ID: 34675936
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
[TBL] [Abstract][Full Text] [Related]
38. Advances in clinical immunotherapy for gastric cancer.
Li K; Zhang A; Li X; Zhang H; Zhao L
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
[TBL] [Abstract][Full Text] [Related]
39. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer.
Lin A; Qi C; Wei T; Li M; Cheng Q; Liu Z; Luo P; Zhang J
Brief Bioinform; 2022 May; 23(3):. PubMed ID: 35395670
[TBL] [Abstract][Full Text] [Related]
40. Toward a Taxonomy for Multi-Omics Science? Terminology Development for Whole Genome Study Approaches by Omics Technology and Hierarchy.
Pirih N; Kunej T
OMICS; 2017 Jan; 21(1):1-16. PubMed ID: 28271979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
